Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

BERLIN--(BUSINESS WIRE)--Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap antibody's potential as a treatment option in indications of high medical relevance. "We are excited to advance our anti-α2ap antibody to the next stage of clinical development in patients with d.

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Bayer's CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.

Bayer CEO says company stands behind glyphosate

A U.S. appeals court on Monday refused to dismiss a lawsuit claiming that Bayer AG's Roundup weedkiller caused cancer, the latest setback in the company's efforts to fend off thousands of similar lawsuits carrying potentially billions of dollars in damages.

US appeals court finds Bayer not shielded from Roundup lawsuits

BOSTON--(BUSINESS WIRE)--TetraScience announces agreement with Bayer AG to ignite innovation by maximizing the value of its scientific data.

Bayer AG Enters Into Agreement With TetraScience to Ignite Innovation by Maximizing the Value of Its Scientific Data

Despite more than $4 billion in U.S. jury verdicts over Bayer's Roundup weedkiller, including a $2.25 billion verdict last week, the company so far has shown no willingness to settle, instead betting that it can greatly reduce, or wipe out, its liability through legal appeals.

As Roundup verdicts pile up, Bayer bets big on US appeals courts

Bayer was ordered to pay $2.25 billion after a Pennsylvania jury unanimously ruled that its Roundup weed killer gave a man cancer.

Bayer to pay $2.25B after jury says Roundup weed killer gave man cancer

An Australian court on Tuesday heard closing arguments in a class action lawsuit alleging that a weedkiller produced by Bayer caused cancer, the first such case in Australia to reach this stage.

Bayer faces Australian test with judge to decide whether weedkiller caused cancer

Shares in Bayer fell 5% on Monday after a Philadelphia jury told the German pharmaceutical company to pay $2.25 billion to a man who says he developed cancer due to using its Roundup branded weedkiller.

Bayer shares slump after court tells firm to pay $2.25 billion over Monsanto weedkiller lawsuit

Bayer shares slumped after the German pharmaceutical and agricultural company was ordered to pay $2.25 billion in damages in the latest setback in its legal battle over its Roundup weed killer.

Bayer Shares Fall After Jury Orders $2.25 Billion in Damages in Roundup Case

Shares in Bayer dropped as much as 5.7% on Monday after the embattled German company was ordered to pay $2.25 billion in damages, the highest amount yet in its ongoing litigation linked to an alleged carcinogenic effect of its Roundup weedkiller.

Bayer shares fall nearly 6% on court order to pay $2.25 bln in damages

Bayer was ordered on Friday to pay $2.25 billion to a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller, the man's attorneys said.

Bayer ordered to pay $2.25 billion in latest Roundup trial

WHIPPANY, N.J. & WOODLAND, Calif.--(BUSINESS WIRE)--A new solar array installation at Bayer's vegetable research and development site in Woodland, CA will provide 70% of the site's electrical energy demand. “With this new installation, the Woodland site is the most onsite solar-powered operation within Bayer globally,” says Enrique Wehlen, Head of Sustainability, Safety, Health & Environments (SSHE) North America at Bayer. The Woodland solar power project follows a recently completed solar.

Bayer Unveils Groundbreaking Solar Energy Projects at Sites in New Jersey and California

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will serve on the Pharmaceuticals Executive Committee and be based in Berlin, Germany. Gerd Krueger, who has led the Radiology unit for the past eight years, will work closely with him on a smooth transition b.

Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California. These presentations underscore Bayer's commitment to advance prostate cancer care. NUBEQA® (darolutamide) data includes post hoc sensitivity analyses from the Phase III ARASENS trial, evaluating overall survival (OS) with NUBEQA and androgen.

Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium

Bayer AG (ETR:BAYN, OTC:BAYZF) will find it tough to hit last year's targets and faces multiple adverse factors in 2024, said Stifel as it downgraded the German pharma giant and cut its share price target.  The US bank removed its 'buy' rating with a switch to a 'hold' stance with a reduced price target of €42 from €68.

Bayer downgraded over 'multiple adverse factors' faced in 2024

Germany's Bayer will continue its expansion into the U.S. despite its November announcement that its promising blood thinner candidate failed to demonstrate superiority over a competing medicine, the drugmaker's pharmaceuticals head Stefan Oelrich said on Monday.

Bayer plans US expansion despite blood thinner drug setback

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

Moderna

Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday.  Founded in 2018 by scientists at UC Berkeley, Metagenomi's revenue to date has come from a trio of collaborations, including one with backer Moderna.

Moderna, Bayer-backed genetic therapies company files for IPO

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in women's healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled into NIRVANA, an exploratory Phase II study to evaluate the efficacy and safety of elinzanetant in women with sleep disturbances associated with menopause (SDM). Together with vasomotor symptoms (also known as VMS or hot flashes) and mood symptoms, sleep disturba.

Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause

BERLIN--(BUSINESS WIRE)--Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints in both studies demonstrating statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. Bot.

Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies

Bayer said its menopausal relief drug eased hot flashes and improved sleep in two late-stage trials, much-needed good news for the German group's pharmaceuticals unit that is reeling from a recent development setback.

Bayer's menopausal relief drug succeeds in late-stage trial

AP Moller - Maersk A/S

Assicurazioni Generali SpA

Bayerische Motoren Werke AG

BNP Paribas SA

Engie SA

Glencore PLC

HSBC Holdings

ING Groep NV

Intesa Sanpaolo SpA

Orange

Stellantis N.V. 

Vodafone Group

In December 2023 - January 2024, Barron's/Fortune analysts-reporters combined to list three sets of stocks: (1) Top 100 of first-ever Euro Fortune 500; (2) 13 Inflation-Proof 2024 stocks; (3) Barron's 10 Favorites for 2024. Those three articles revealed 98 equities, with 84 paying dividends, and focused on every sector, except real estate. The stocks ranged from 0.03% to 45.15% in annual yield and ranged -95.60% to 194.10% in one-year price target upsides per broker analysts.

46 Ideal 2024 Fortune And Barron's DiviDogs

Bank of America

Banco de Chile

British American Tobacco

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Altria

Realty Income Corp

AT&T

Verizon

Zurich Insurance Group AG

High dividend yield companies are essential components within a well-balanced and diversified dividend portfolio, particularly for those seeking to generate substantial additional income via dividends. In this article, I will present 10 high dividend yield companies that are worth considering an investment in due to their attractive Valuation, high Dividend Yield, and financial health. 3 of the 10 selected picks provide investors with a Dividend Yield [FWD] above 9%: Altria (9.76%), British American Tobacco (9.55%) and Banco de Chile (9.40%).

Up To 10% Yields: My Top 10 High Dividend Yield Companies For January 2024

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

WHIPPANY, N.J.--(BUSINESS WIRE)--On Friday, December 22, a jury reached a defense verdict in the Jones Roundup™ product liability trial before Judge Patrick Palacios in the Superior Court of California, San Benito County, and the Company issued the following statement. “The jury's verdict in favor of the Company brings this trial to a successful conclusion and is consistent with the evidence in this case that Roundup™ does not cause cancer and is not responsible for the plaintiff's illness. The.

Bayer Statement on Win in Jones Roundup™ Trial

News for Bayer AG Stock (BAYRY)